Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy.

Monica PulighedduMiriam MelisGiuliano PillollaGiulia MilioliLiborio ParrinoGiovanni Mario TerzanoSonia AroniClaudia SaghedduFrancesco MarrosuMarco PistisAnna Lisa Muntoni

Published in: Epilepsia (2017)

Our preclinical and clinical studies suggest PPARα as a novel disease-modifying target for antiepileptic drugs due to its ability to regulate dysfunctional nAChRs.

Keyphrases

blood pressure
obstructive sleep apnea
cell therapy
insulin resistance
working memory
functional connectivity
sleep apnea
sleep quality
type diabetes
stem cells
metabolic syndrome
adipose tissue
physical activity
bone marrow
mesenchymal stem cells